Condition: Congenital Antithrombin Deficiency · Sponsor: Octapharma
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical procedures or parturition.
This description comes directly from the study's public registry record.
Sigurd Knaub · +41554512141 · Sigurd.Knaub@octapharma.com
Always discuss trial participation with your own doctor first.
| Georgetown University | Washington D.C., District of Columbia, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Bleeding and Clotting Disorders Institute | Peoria, Illinois, United States | Recruiting |
| Weill Cornell Medicine | New York, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Yeolyan Hematology and Oncology Centre | Yerevan, Armenia | Recruiting |
| Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie und Hämostaseologie | Vienna, Austria | Recruiting |
| Centre for Thrombosis and Haemaostasis | Nymburk, Czechia | Recruiting |
| Centre de Référence de l'Hémophilie Unité d'Hémostase Clinique Hôpital Cardiologique Louis Pradel | Bron, France | Recruiting |
| University Hospital of Reims | Reims, France | Recruiting |
| Centre Hospitalier Universitaire de Rouen (CHU de Rouen) - Centre de Traitement des Maladies Hemorragiques (CRTH) (Centre d'Hemophiles) | Rouen, France | Recruiting |
| Aversi Clinic | Tbilisi, Georgia | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.